Veru Inc.’s (VERU) request for Emergency Use Authorization of Sabizabulin for hospitalized COVID-19 patients who are at high risk for acute respiratory distress syndrome (ARDS) is scheduled to be discussed by the FDA’s Pulmonary-Allergy Drugs Advisory Committee on November 9, 2022.Sabizabulin, an oral, microtubule disruptor, is a new dual antiviral and anti-inflammatory agent.In clinical trials, Sabizabulin treatment demonstrated a 55.2% relative reduction of mortality in hospitalized moderate to severe COVID-19 patients at high risk for ARDS and death compared to placebo.VERU closed Tuesday’s (Oct 25, 2022) trading at $11.63, up 6.80%.